Category: Cardiac ImplantsSyndicate content

Sorin wins FDA nod for Memo3d ReChord mitral annuloplasty ring

December 18, 2014 by Mark Hollmer

Sorin Group is beginning a U.S. rollout of a new surgical implant ring for addressing mitral valve repair issues.

Sorin wins FDA nod for Memo3d ReChord annuloplasty ring

Italy's Sorin Group (BIT:SRN) nailed down FDA clearance for a new surgical implant designed for use in mitral valve repair.

UPDATE: 3rd FDA panel vote barely favors Boston Scientific's Watchman anti-stroke device

October 9, 2014 by Brad Perriello

An FDA advisory panel's unprecedented 3rd hearing over Boston Scientific's Watchman anti-stroke device barely favors the cardiac implant.

UPDATE: 3rd FDA panel vote barely favors Boston Scientific's Watchman anti-stroke device

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

FDA panel offers mixed view on Boston Scientific Watchman device

October 8, 2014 by MassDevice

An FDA advisory panel gives a mixed view in its unprecedented 3rd review of Boston Scientific's Watchman anti-stroke device.

FDA panel offers mixed view on Boston Scientific Watchman device

FDA doubtful on new Watchman data from Boston Scientific

October 6, 2014 by Brad Perriello

The FDA expresses some doubts about new data from Boston Scientific on its Watchman anti-stroke device.

FDA doubtful on new Watchman data from Boston Scientific

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

LoneStar Heart wins CE Mark for hydrogel heart implant

October 1, 2014 by Alex Soule

LoneStar Heart wins CE Mark approval in the European Union for its Algisyl-LVR hydrogel implant, a hydrogel implant designed to treat heart failure.

LoneStar Heart wins CE Mark for hydrogel heart implant

Laguna Hills, Calif.-based LoneStar Heart said it won CE Mark approval in the European Union for its Algisyl-LVR hydrogel implant for the treatment of advanced heart failure. 

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

New data not so good for Boston Scientific's Watchman anti-stroke device

September 22, 2014 by Scott Wooldridge

New data presented last week at the annual Transcatheter Cardiovascular Therapies meeting showed Boston Scienfitic's Watchman anti-stoke device to be comparable to treatment with the anti-coagulant warfarin.

New data not so good for Boston Scientific's Watchman anti-stroke device

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp